Clinical trial
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
NCT00064129 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00064129 |
|---|---|
| Title | Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer |
| Official title | A Phase I Study of Repetitive Dosing of Anti-CTLA-4 Antibody (Ipilimumab) in Combination With GM-CSF in Patients With Metastatic, Androgen-Independent Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7 |
| Intervention type | Biological, Other |
| Interventions | Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim |
| Enrollment | 42 |
| Start date | May 13, 2003 |
| Primary completion | Jan 10, 2011 |
| Completion | Oct 1, 2012 |
| First posted | Jul 9, 2003 |
| Last update posted | Jul 30, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: